We will rely on you to help lend your voice and support the biotechnology industry.
Bringing new treatments to patients, support public policies that promote innovation, improve patient access.
BIO International ConventionJune 3-6, 2019
BIO World Congress on Industrial Biotechnology and Ag TechJuly 8-11, 2019
BIO Industry Analysis Reports >>
Save. Advocate. Connect. Join Us.
A listing of all BIO members and subsidiaries.
February 11 - 12, 2019 | New York, New York
Oyster Point is a clinical-stage pharmaceutical company leveraging neuroscience to develop and commercialize novel therapies for ophthalmic diseases. The lead candidate has completed phase 2 and is an innovative therapeutic with the potential become the standard of care for Dry Eye Disease (DED) with $2B+ annual global revenue potential. DED affects over 30 million adults in the US and over 340 million people globally. The company’s leadership team has extensive experience developing and commercializing ophthalmology therapies at companies including Genentech, Allergan, OptiMedica, Oculeve, Ophthotech, Guidant, and Eyetech. Oyster Point was founded in 2015 by neuroscientist and entrepreneur Dr. Michael Ackermann, past CEO of Oculeve (acquired by Allergan). The company is preparing to initiate Phase 3 trials in 2019. The current investors are NEA and Versant Ventures. Oyster Point is headquartered in Princeton, NJ.